- Home
- DD vs EW Comparison
DD vs EW Comparison
Compare DD & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DD
- EW
- Stock Information
- Founded
- DD 2015
- EW 1958
- Country
- DD United States
- EW United States
- Employees
- DD N/A
- EW N/A
- Industry
- DD Major Chemicals
- EW Industrial Specialties
- Sector
- DD Industrials
- EW Health Care
- Exchange
- DD Nasdaq
- EW Nasdaq
- Market Cap
- DD 34.2B
- EW 40.7B
- IPO Year
- DD N/A
- EW 2000
- Fundamental
- Price
- DD $66.27
- EW $74.61
- Analyst Decision
- DD Buy
- EW Buy
- Analyst Count
- DD 14
- EW 20
- Target Price
- DD $84.36
- EW $79.45
- AVG Volume (30 Days)
- DD 3.3M
- EW 4.6M
- Earning Date
- DD 05-02-2025
- EW 04-23-2025
- Dividend Yield
- DD 2.48%
- EW N/A
- EPS Growth
- DD N/A
- EW 201.77
- EPS
- DD N/A
- EW 7.02
- Revenue
- DD $12,521,000,000.00
- EW $5,522,300,000.00
- Revenue This Year
- DD $6.04
- EW $10.07
- Revenue Next Year
- DD $4.54
- EW $9.65
- P/E Ratio
- DD N/A
- EW $10.70
- Revenue Growth
- DD 4.51
- EW N/A
- 52 Week Low
- DD $53.77
- EW $58.93
- 52 Week High
- DD $90.06
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- DD 50.89
- EW 56.61
- Support Level
- DD $64.09
- EW $74.25
- Resistance Level
- DD $68.37
- EW $77.12
- Average True Range (ATR)
- DD 1.80
- EW 1.85
- MACD
- DD 0.75
- EW 0.11
- Stochastic Oscillator
- DD 78.72
- EW 70.44
About DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to spin off its electronics business by the end of 2025.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.